Linked Life Data

10362119

Source:http://linkedlifedata.com/resource/pubmed/id/10362119

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10362119rdf:typepubmed:Citationlld:pubmed
pubmed-article:10362119lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:10362119lifeskim:mentionsumls-concept:C0439849lld:lifeskim
pubmed-article:10362119lifeskim:mentionsumls-concept:C0235974lld:lifeskim
pubmed-article:10362119lifeskim:mentionsumls-concept:C0080055lld:lifeskim
pubmed-article:10362119lifeskim:mentionsumls-concept:C0376515lld:lifeskim
pubmed-article:10362119lifeskim:mentionsumls-concept:C0449258lld:lifeskim
pubmed-article:10362119lifeskim:mentionsumls-concept:C0017262lld:lifeskim
pubmed-article:10362119lifeskim:mentionsumls-concept:C0445223lld:lifeskim
pubmed-article:10362119lifeskim:mentionsumls-concept:C1552599lld:lifeskim
pubmed-article:10362119lifeskim:mentionsumls-concept:C0205349lld:lifeskim
pubmed-article:10362119lifeskim:mentionsumls-concept:C1704787lld:lifeskim
pubmed-article:10362119lifeskim:mentionsumls-concept:C2911684lld:lifeskim
pubmed-article:10362119lifeskim:mentionsumls-concept:C0185117lld:lifeskim
pubmed-article:10362119pubmed:issue7lld:pubmed
pubmed-article:10362119pubmed:dateCreated1999-6-24lld:pubmed
pubmed-article:10362119pubmed:abstractTextp53 and Bcl-2 are two important factors related to apoptosis and tumorigenesis. In this study, a series of 52 cases of pancreatic carcinoma (PC) were investigated using an immunohistochemical assay to determine whether altered expression of Bcl-2 and p53 has an impact on the progression of this malignancy. Cytoplasmic immunoreactivity for Bcl-2 and nuclear staining of p53 was found in 12 (23.1%) and 32 (63.5%) cases of PC respectively. Furthermore, an inverse correlation between the expression of p53 and Bcl-2 existed in this series (P < 0.01). In a subgroup, the proportion of tumours showing that p53-positive and Bcl-2-negative staining was increased with increasing histological grade and clinical stage (P < 0.05), and moreover, the survival period of those patients whose tumour had this staining was shorter than those with other staining patterns of combined p53 and Bcl-2 (P < 0.05). Therefore, it is concluded that simultaneously aberrant expression of Bcl-2 and p53 may confer PC with more malignant clinicopathological characteristics.lld:pubmed
pubmed-article:10362119pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10362119pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10362119pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10362119pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10362119pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10362119pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10362119pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10362119pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10362119pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10362119pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10362119pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10362119pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10362119pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10362119pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10362119pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10362119pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10362119pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10362119pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10362119pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10362119pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10362119pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10362119pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10362119pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10362119pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10362119pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10362119pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10362119pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10362119pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10362119pubmed:languageenglld:pubmed
pubmed-article:10362119pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10362119pubmed:citationSubsetIMlld:pubmed
pubmed-article:10362119pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10362119pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10362119pubmed:statusMEDLINElld:pubmed
pubmed-article:10362119pubmed:monthJunlld:pubmed
pubmed-article:10362119pubmed:issn0007-0920lld:pubmed
pubmed-article:10362119pubmed:authorpubmed-author:WatanabeHHlld:pubmed
pubmed-article:10362119pubmed:authorpubmed-author:SawabuNNlld:pubmed
pubmed-article:10362119pubmed:authorpubmed-author:YamaguchiYYlld:pubmed
pubmed-article:10362119pubmed:authorpubmed-author:HuY XYXlld:pubmed
pubmed-article:10362119pubmed:authorpubmed-author:OhtsuboKKlld:pubmed
pubmed-article:10362119pubmed:authorpubmed-author:FOXJ MJMlld:pubmed
pubmed-article:10362119pubmed:authorpubmed-author:OkalWWlld:pubmed
pubmed-article:10362119pubmed:authorpubmed-author:MotooYYlld:pubmed
pubmed-article:10362119pubmed:issnTypePrintlld:pubmed
pubmed-article:10362119pubmed:volume80lld:pubmed
pubmed-article:10362119pubmed:ownerNLMlld:pubmed
pubmed-article:10362119pubmed:authorsCompleteYlld:pubmed
pubmed-article:10362119pubmed:pagination1075-9lld:pubmed
pubmed-article:10362119pubmed:dateRevised2009-11-18lld:pubmed
pubmed-article:10362119pubmed:meshHeadingpubmed-meshheading:10362119...lld:pubmed
pubmed-article:10362119pubmed:meshHeadingpubmed-meshheading:10362119...lld:pubmed
pubmed-article:10362119pubmed:meshHeadingpubmed-meshheading:10362119...lld:pubmed
pubmed-article:10362119pubmed:meshHeadingpubmed-meshheading:10362119...lld:pubmed
pubmed-article:10362119pubmed:meshHeadingpubmed-meshheading:10362119...lld:pubmed
pubmed-article:10362119pubmed:meshHeadingpubmed-meshheading:10362119...lld:pubmed
pubmed-article:10362119pubmed:meshHeadingpubmed-meshheading:10362119...lld:pubmed
pubmed-article:10362119pubmed:meshHeadingpubmed-meshheading:10362119...lld:pubmed
pubmed-article:10362119pubmed:meshHeadingpubmed-meshheading:10362119...lld:pubmed
pubmed-article:10362119pubmed:meshHeadingpubmed-meshheading:10362119...lld:pubmed
pubmed-article:10362119pubmed:year1999lld:pubmed
pubmed-article:10362119pubmed:articleTitleBcl-2 expression related to altered p53 protein and its impact on the progression of human pancreatic carcinoma.lld:pubmed
pubmed-article:10362119pubmed:affiliationDepartment of Internal Medicine and Medical Oncology, Cancer Research Institute, Kanazawa University, Japan.lld:pubmed
pubmed-article:10362119pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10362119pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10362119lld:pubmed